Induction chemotherapy for advanced head and neck cancers: A literature review

Abstract Induction chemotherapy before surgery and/or radiotherapy for previously untreated head and neck carcinoma results in greater response rates than chemotherapy for recurrent head and neck carcinomas. Its theoretical advantages are presented. Most studies using induction chemotherapy are nonrandomized, uncontrolled pilot efforts. Multiple‐drug regimens result in greater response rates than single agents, and multiple courses result in greater response rates than single courses. Prognostic factors are discussed. Toxicities are tolerable, except for several reported regimens combining cisplatin, bleomycin, and metho‐trexate. Induction chemotherapy for head and neck cancer is promising and needs further studies with controlled, randomized trials with long‐term follow‐up.